Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | ALKBH3 | Q96Q83 | 7/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | MT-CO1 | P00395 | 2/20 | 0.45 |
| ▸ | MT-CO2 | P00403 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3051829 | 0.89 | ALKBH3 (0.47) | KDM4ESMN1; SMN2ALKBH3THRBKAT8 | |
| SCHEMBL4285011 | 0.72 | RAB9A (0.71) | KDM4ENPC1SMN1; SMN2POLBRAB9A | |
| SCHEMBL245171 | 0.70 | SCD (0.67) | KDM4ENPC1SMN1; SMN2POLBRAB9A | |
| SCHEMBL14162432 | 0.69 | RAB9A (0.46) | KDM4ENPC1SMN1; SMN2POLBRAB9A | |
| SCHEMBL15258790 | 0.68 | KDM4E (0.81) | KDM4EALKBH3KAT8MT-CO1MT-CO2 | |
| SCHEMBL2069278 | 0.68 | RAB9A (1.00) | KDM4ENPC1SMN1; SMN2POLBRAB9A | |
| SCHEMBL2564163 | 0.65 | KDM4E (0.67) | KDM4EALKBH3KAT8MT-CO1MT-CO2 | |
| SCHEMBL3035110 | 0.65 | RAB9A (0.61) | KDM4ENPC1SMN1; SMN2POLBRAB9A | |
| SCHEMBL627033 | 0.64 | SMN1; SMN2 (0.52) | KDM4ENPC1SMN1; SMN2POLBRAB9A | |
| SCHEMBL8345831 | 0.63 | RAB9A (0.86) | KDM4ENPC1SMN1; SMN2POLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101595105-B | 2-substituted 5-membered heterocycles as SCD inhibitors | NOVARTIS AG | 2013-01-23 | — | — | CN | disclosed |
| US-8258160-B2 | SCD1 inhibitors triazole and tetrazole compounds | NOVARTIS AG (CH) | 2012-09-04 | — | — | US | disclosed |
| US-8258160-B2 | SCD1 inhibitors triazole and tetrazole compounds | NOVARTIS AG (CH) | 2012-09-04 | — | — | US | disclosed |
| US-8258160-B2 | SCD1 inhibitors triazole and tetrazole compounds | NOVARTIS AG (CH) | 2012-09-04 | — | — | US | disclosed |
| US-20100029722-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20100029722-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20100029722-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| CN-101595105-A | 5 membered heterocyclic compounds that replace as the 2-of SCD inhibitor | NOVARTIS AG XENON PHARMACEUTIC (CH) | 2009-12-02 | — | — | CN | disclosed |
| EP-2121671-A1 | 2-SUBSTITUTED 5-MEMBERED HETEROCYCLES AS SCD INHIBITORS | Novartis AG (CH) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008074835-A1 | 2-SUBSTITUTED 5-MEMBERED HETEROCYCLES AS SCD INHIBITORS | NOVARTIS AG (CH) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029722-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | KDM4E 683/4885NPC1 228/4885SMN1; SMN2 3581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.